Dec 19, 2018

ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center

May 15, 2018

NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University

July 5, 2017

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

February 19, 2016

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups

January 8, 2014

ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology